Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lonza | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lonza

Pharma & Biotech sales down 8%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza

FY Revenues: CHF 3.6 billion  (-4%)

FY Earnings: CHR 87 million (-44%)

Comments: Pharma & Biotech sales, which include Lonza’s custom manufacturing and Bioscience sectors, were down 8% to CHF 1.4 billion. Revenues were impacted by product portfolio optimizations and the initiation of several major projects. The first quarter saw a scheduled production stop for the build-out at the company’s ADC plant in Visp. Its large-scale mammalian cell culture facility in Singapore implemented multiple plant adaptations, and the company began the phasedown of the Hopkinton, MA microbial biologics plant, which incurred restructuring costs of CHF 46 million. Specialty Ingredients sales were CHF 2.2 billion, down 1%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters